---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-168182"
form_type: "8-K"
ticker: "RCEL"
cik: "0001762303"
company_name: "AVITA Medical, Inc."
filed_at: "2023-06-16T23:59:59+00:00"
generated_at: "2026-06-13T23:00:12.768119+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# AVITA Medical names David O'Toole CFO; $450K salary, 150K options

## Summary
- David O'Toole appointed CFO effective June 15, 2023; brings 30+ years biotech/life sciences finance experience.
- Annual base salary of $450,000; eligible for performance bonus up to 40% of base (max 90% combined).
- Granted 150,000 stock options under 2020 Omnibus Plan vesting in 3 equal annual installments.
- On termination without cause: 12 months base salary plus health benefits, unvested options accelerated for 3 months.
- Most recently CFO of Opiant Pharmaceuticals (acquired by Indivior); previously CFO of Soleno Therapeutics.

## SEC filing metadata
- accession: 0001193125-23-168182
- form_type: 8-K
- ticker: RCEL
- cik: 0001762303
- company_name: AVITA Medical, Inc.
- filed_at: 2023-06-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1762303/000119312523168182/0001193125-23-168182-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1762303/000119312523168182/d522351d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-168182
- JSON: https://secwatch.observer/filing/0001193125-23-168182.json
- Plain text: https://secwatch.observer/filing/0001193125-23-168182.txt

## Key facts
- Executive change
  David O'Toole was appointed as Chief Financial Officer at AVITA Medical, Inc..
  - Action: appointed
  - Role: Chief Financial Officer
  source text: AVITA Medical, Inc. (the “Company”) entered into an Executive Employment Agreement (the “Agreement”) with David O’Toole with an effective date of June 15, 2023 (the “Effective Date”), pursuant to which Mr. O’Toole will serve as the Company’s Chief Financial Officer.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1762303/000119312523168182/0001193125-23-168182-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.